Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

Artificial intelligence is an advanced method to identify novel anticancer targets and discover
novel drugs from biology networks because the networks can effectively preserve and …

Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …

Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …

We present a proteogenomic study of 108 human papilloma virus (HPV)-negative head and
neck squamous cell carcinomas (HNSCCs). Proteomic analysis systematically catalogs …

We report a comprehensive proteogenomics analysis, including whole-genome sequencing,
RNA sequencing, and proteomics and phosphoproteomics profiling, of 218 tumors across 7 …

The integration of mass spectrometry-based proteomics with next-generation DNA and RNA
sequencing profiles tumors more comprehensively. Here this" proteogenomics" approach …

Glioblastoma (GBM) is the most aggressive nervous system cancer. Understanding its
molecular pathogenesis is crucial to improving diagnosis and treatment. Integrated analysis …

To improve the understanding of chemo-refractory high-grade serous ovarian cancers
(HGSOCs), we characterized the proteogenomic landscape of 242 (refractory and sensitive) …

Abstract Background: Angiopoietin-like 4 (ANGPTL4) belongs to the angiopoietin-like
protein family and mediates the inhibition of lipoprotein lipase activity. Emerging evidence …